Search clinical trials for: PLD, cyclophosphamide, trastuzumab, paclitaxel

Total 608 results

National Cancer Centre, Singapore

Terminated

Paclitaxel, Doxorubicin, and Cyclophosphamide With Or Without Carboplatin in Treating Women With Locally Advanced Breast Cancer That Can Be Removed by Surgery

Breast Cancer

Singapore
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Breast Cancer

United States
Fudan University

Recruiting

Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer (PANSY)

Breast Cancer

China
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham...

Completed

Preoperative Herceptin and Navelbine for Breast Cancer

Breast Cancer | Stage II Breast Cancer | Stage III Breast Cancer

United States
Haukeland University Hospital
Pfizer; AstraZeneca; Helse Vest

Active, not recruiting

PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial (PETREMAC)

Breast Cancer

Norway
Leo W. Jenkins Cancer Center

Terminated

Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer

Breast Cancer

United States
EBMT Solid Tumors Working Party

Completed

High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery

Ovarian Cancer

Switzerland, Spain, United Kingdom, Italy, Slovakia, Germany, Belgium, Austria, Czech Republic
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer

Ovarian Cancer

United States, Canada
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Peripheral Stem Cell Transplantation With or Without Stromagen Following Chemotherapy in Treating Women With Metastatic Breast Cancer

Breast Cancer

United States
Cancer Trials Ireland

Completed

A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer (TH V THL)

Metastatic Breast Cancer

Spain, Ireland, Israel, Finland, Portugal, France, Germany, Norway
Daiichi Sankyo
AstraZeneca

Recruiting

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Gastroesophageal Junction Adenocarcinoma | Gastric Cancer, Adenocarcinoma

Hong Kong, Korea, Republic of, France, United Kingdom, Spain, China, Ireland, Brazil, Japan, Singapore, Belgium, Israel, Russian Federation, Argentina, Chile, Hungary, Poland, Portugal, Taiwan, Turkey, Ukraine, Germany, Romania, Italy
National Institute of Oncology, Hungary

Not yet recruiting

Neoadjuvant Treatment of Breast Cancer

Breast Cancer

Hungary
University of Southern California
National Cancer Institute (NCI)

Terminated

Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer

HER2-positive Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
ETOP IBCSG Partners Foundation

Completed

MEtronomic TrEatment Option in Advanced bReast cAncer (METEORA-II)

Breast Cancer

Italy
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Breast Cancer

United States, Puerto Rico, Canada
Swiss Group for Clinical Cancer Research

Completed

Metronomic Therapy in Metastatic Breast Cancer.

Breast Cancer

Switzerland
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Pharmacia; Amgen

Completed

Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer

Breast Cancer

United States
Cancer Institute and Hospital, Chinese Academy...

Unknown

The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC

Breast Cancer

China
German Breast Group
Celgene Corporation; Amgen

Completed

Denosumab as an add-on Neoadjuvant Treatment (GeparX) (GeparX)

Inflammatory Breast Cancer | HER2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage III

Germany
Fudan University

Unknown

Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)

Early Breast Cancer

China
ImmunityBio, Inc.

Active, not recruiting

QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.

Non Small Cell Lung Cancer

United States
Hoffmann-La Roche

Active, not recruiting

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

HER2-positive Early Breast Cancer

China
Peking University

Recruiting

Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma

Peripheral T-cell Lymphoma

China
University of Washington
Bristol-Myers Squibb; GlaxoSmithKline; Amgen

Terminated

Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial

Breast Cancer

United States
GlaxoSmithKline

Completed

Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.

Neoplasms, Breast

United States
Japan Breast Cancer Research Group
Eisai Co., Ltd.

Recruiting

A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab

Breast Cancer

Japan
Advenchen Laboratories, LLC

Active, not recruiting

Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) (AL3818)

Fallopian Tube Carcinoma | Cervical Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma

Korea, Republic of, Spain, United States, United Kingdom, China, Italy
Japan Breast Cancer Research Group
Chugai Pharmaceutical

Unknown

A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer (PRECIOUS)

HER2-positive Locally Advanced or Metastatic Breast Cancer

Japan
wang shusen

Recruiting

Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy (SMA-BC-002)

Breast Neoplasms

China
M.D. Anderson Cancer Center
Genentech, Inc.

Completed

Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer

Breast Cancer

United States
Institut fuer Frauengesundheit
Merck Sharp & Dohme LLC; Celgene Corporation

Completed

Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC (NIB)

Malignant Neoplasm of Breast

Germany
Arog Pharmaceuticals, Inc.

Completed

Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma

Esophagogastric Adenocarcinoma

United States
National Cancer Institute (NCI)

Completed

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

Recurrent Prostate Cancer | Fallopian Tube Cancer | Bone Metastases | Lung Metastases | Stage III Renal Cell Cancer | Liver Metastases | Recurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer | Inflammatory Breast Cancer | Metastatic Transitional Cell Cancer of the... and other conditions

United States
University of Texas Southwestern Medical Center
Merck Sharp & Dohme LLC; Breast Cancer Research Foundation

Active, not recruiting

Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab

Breast Cancer | HER2-positive Breast Cancer

United States
Spanish Breast Cancer Research Group
Bristol-Myers Squibb

Completed

Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients

Metastatic Breast Cancer

Spain
Novartis Pharmaceuticals
Breast International Group; SOLTI Breast Cancer Research Group

Completed

Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study (Neo ALTTO)

Neoplasms, Breast

France, Spain, United Kingdom, Belgium, Argentina, Czechia, Germany, Italy, Norway, Russian Federation, Sweden, Taiwan, Hong Kong, Brazil, Hungary, India, Korea, Republic of, Pakistan, Peru, Romania, South Africa, Ukraine, Canada, Lit...
Memorial Sloan Kettering Cancer Center
GlaxoSmithKline

Completed

Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer

HER2-Positive Early Stage Breast Cancer

United States
GlaxoSmithKline

Withdrawn

Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer (ELATE)

Neoplasms, Breast

Hungary, Norway, Austria, Spain
The Netherlands Cancer Institute
Roche Pharma AG; Borstkanker Onderzoek Groep

Active, not recruiting

Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer (Triple-B)

Breast Cancer

Netherlands
Immatics Biotechnologies GmbH

Completed

IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101) (IMA910-101)

Colorectal Carcinoma

United Kingdom, Romania, Belgium, Bulgaria, Germany, Hungary, Latvia, Poland, Serbia
Bristol-Myers Squibb

Completed

Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy

Breast Cancer | Solid Tumor

United States
Shanghai Henlius Biotech

Not yet recruiting

to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer
Barretos Cancer Hospital
University of Sao Paulo

Unknown

Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer (LABC)

Breast Cancer

Brazil
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Terminated

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer (ETC)

Ovarian Cancer

United States
Chipscreen Biosciences, Ltd.

Completed

Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer

Non-small-cell Lung Cancer

China
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Breast Cancer

United States, Puerto Rico
AstraZeneca

Completed

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation

United States, Canada, Netherlands
Azienda Ospedaliero-Universitaria di Modena

Unknown

Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer

Breast Cancer

Italy
Shengjing Hospital

Recruiting

A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer

Stage II-III Breast Cancer

China
Hoffmann-La Roche

Completed

A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer

Breast Cancer

Turkey, Algeria, Morocco, Saudi Arabia, Tunisia

Search clinical trials for: PLD, cyclophosphamide, trastuzumab, paclitaxel

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations